keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic Weight Gain

keyword
https://www.readbyqxmd.com/read/28408348/design-and-in-vivo-evaluation-of-solid-lipid-nanoparticulate-systems-of-olanzapine-for-acute-phase-schizophrenia-treatment-investigations-on-antipsychotic-potential-and-adverse-effects
#1
Emil Joseph, Satish Reddi, Vibhu Rinwa, Garima Balwani, Ranendra Saha
The present paper discusses the design, characterization and in vivo evaluation of glyceryl monostearate nanoparticles of Olanzapine, an atypical antipsychotic drug for acute schizophrenia treatment, during which hospitalization is mandatory and adverse effects are at its peak. The solid lipid nanoparticulate system was obtained by emulsification-ultra sonication technique wherein three factors such as solid lipid content, concentration of surfactant and drug: solid lipid ratio were selected at three different levels in order to study their influence on significant characteristic responses such as particle size, encapsulation efficiency and drug content...
April 10, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28407229/weight-gain-with-add-on-second-generation-antipsychotics-in-bipolar-disorder-a-naturalistic-study
#2
H Najar, E Joas, M Kardell, E Pålsson, M Landén
OBJECTIVE: Our aim was to investigate the prevalence and magnitude of weight gain in-patients with bipolar disorder when treated with a second-generation antipsychotic as an add-on treatment to a mood stabilizer in routine clinical practice. METHODS: Data were derived from the quality register for bipolar disorder in Sweden (BipoläR). Patients with bipolar disorder who started add-on treatment with a SGA (n = 575) were compared at next yearly follow-up with age and sex matched patients who were only treated with a mood stabilizer (n = 566)...
April 13, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28400260/prevention-of-the-adverse-effects-of-olanzapine-on-lipid-metabolism-with-the-antiepileptic-zonisamide
#3
Aneta Stefanidis, Matthew J Watt, Michael A Cowley, Brian J Oldfield
BACKGROUND: Atypical antipsychotic drugs, particularly olanzapine, represent a mainstay in the treatment of psychoses; however, their use is commonly associated with weight gain and diabetes. The aim of this study was to determine whether combined administration of olanzapine and zonisamide can be used to prevent olanzapine-induced metabolic disturbances. METHODS AND RESULTS: These experiments involved female Sprague Dawley rats (n = 6-8/group) that were administered olanzapine, either acutely (6 mg/kg, s...
April 8, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28383359/amantadine-for-antipsychotic-related-weight-gain-meta-analysis-of-randomized-placebo-controlled-trials
#4
Wei Zheng, Shibin Wang, Gabor S Ungvari, Chee H Ng, Xin-Hu Yang, Yu-Hong Gu, Ming Li, Ying-Qiang Xiang, Yu-Tao Xiang
PURPOSE: Weight gain associated with antipsychotics in schizophrenia has been an ongoing concern. This meta-analysis examined the efficacy and safety of amantadine as an adjunctive treatment of weight gain in schizophrenia by systematically searching and analyzing randomized controlled trials (RCTs). RCTs comparing adjunctive amantadine with placebo in adult patients with schizophrenia were included in the meta-analysis. METHODS: Two independent investigators searched the literature and extracted data...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28377074/metabolic-side-effects-induced-by-olanzapine-treatment-are-neutralized-by-cb1-receptor-antagonist-compounds-co-administration-in-female-rats
#5
P Lazzari, V Serra, S Marcello, M Pira, A Mastinu
Weight gain is an important side effect of most atypical antipsychotic drugs such as olanzapine. Moreover, although many animal models with metabolic side effects have been well defined, the interaction with other pathways has to be considered. The endocannabinoid system and the CB1 receptor (CB1R) are among the most promising central and peripheral targets involved in weight and energy balance. In this study we developed a rat model based 15-days treatment with olanzapine that shows weight gain and an alteration of the blood parameters involved in the regulation of energy balance and glucose metabolism...
April 1, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28368577/classics-in-chemical-neuroscience-aripiprazole
#6
Austen B Casey, Clinton E Canal
Aripiprazole was the first antipsychotic developed to possess agonist properties at dopamine D2 autoreceptors, a groundbreaking strategy that presented a new vista for schizophrenia drug discovery. The dopamine D2 receptor is the crucial target of all extant antipsychotics, and all developed prior to aripiprazole were D2 receptor antagonists. Extensive blockade of these receptors, however, typically produces extrapyramidal (movement) side effects, which plagued first-generation antipsychotics, such as haloperidol...
April 13, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28347393/brain-volume-changes-over-the-first-year-of-treatment-in-schizophrenia-relationships-to-antipsychotic-treatment
#7
R Emsley, L Asmal, S du Plessis, B Chiliza, L Phahladira, S Kilian
BACKGROUND: Progressive brain volume reductions have been described in schizophrenia, and an association with antipsychotic exposure has been reported. METHODS: We compared percentage changes in grey and white matter volume from baseline to month 12 in 23 previously antipsychotic-naïve patients with a first episode of schizophrenia or schizophreniform disorder who were treated with the lowest effective dose of flupenthixol decanoate depot formulation, with 53 matched healthy individuals...
March 28, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28347259/metformin-for-antipsychotic-induced-weight-gain-statistical-curiosities
#8
Ekta Franscina Pinto, Biju George, Sagar Karia, Chittaranjan Andrade
No abstract text is available yet for this article.
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28347258/depot-risperidone-induced-adverse-metabolic-alterations-in-female-rats
#9
Katerina Horska, Jana Ruda-Kucerova, Michal Karpisek, Pavel Suchy, Radka Opatrilova, Hana Kotolova
Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague-Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed...
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28339282/melatonin-for-reducing-weight-gain-following-administration-of-atypical-antipsychotic-olanzapine-for-adolescents-with-bipolar-disorder-a-randomized-double-blind-placebo-controlled-trial
#10
Seyed-Ali Mostafavi, Mahmoud Solhi, Mohammad-Reza Mohammadi, Shahin Akhondzadeh
OBJECTIVES: We aimed to evaluate melatonin effectiveness in weight gain reduction following olanzapine use for 11-17-year-old bipolar disorder patients. EXPERIMENTAL DESIGN: Seventy-seven adolescent outpatients, subsequent to their initial diagnosis of bipolar I disorder by a psychiatrist, entered this study. After assessing inclusion and exclusion criteria, 48 patients consented to participate. Twenty-four patients were allocated to receive olanzapine, lithium carbonate, and melatonin, and 24 patients were allocated to receive olanzapine, lithium carbonate, and placebo by simple randomization...
March 24, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28335658/dopamine-antagonists-for-treatment-resistance-in-autism-spectrum-disorders-review-and-focus-on-bdnf-stimulators-loxapine-and-amitriptyline
#11
REVIEW
Jessica A Hellings, L Eugene Arnold, Joan C Han
Drug development and repurposing are urgently needed for individuals with autism spectrum disorders (ASD) and psychiatric comorbidity, which often presents as aggression and self-injury. Areas covered: We review dopamine antagonists, including classical and atypical, as well as unconventional antipsychotics in ASD. The older antipsychotic loxapine is discussed in terms of preliminary albeit limited evidence in ASD. Emerging promise of amitriptyline in ASD is discussed, together with promising BDNF effects of loxapine and amitriptyline...
April 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28333365/clozapine-combined-with-different-antipsychotic-drugs-for-treatment-resistant-schizophrenia
#12
REVIEW
Sarah Barber, Uwaila Olotu, Martina Corsi, Andrea Cipriani
BACKGROUND: Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine. OBJECTIVES: To determine the clinical effects of various clozapine combination strategies with antipsychotic drugs in people with treatment-resistant schizophrenia both in terms of efficacy and tolerability...
March 23, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28327672/tox-and-adipoq-gene-polymorphisms-are-associated-with-antipsychotic-induced-weight-gain-in-han-chinese
#13
Shen Li, Chengai Xu, Yuan Tian, Xueshi Wang, Rui Jiang, Miaomiao Zhang, Lili Wang, Guifu Yang, Ying Gao, Chenyu Song, Yukun He, Ying Zhang, Jie Li, Wei-Dong Li
To find the genetic markers related to the antipsychotic-induced weight gain (AIWG), we analyzed associations among candidate gene single-nucleotide polymorphisms (SNPs) and quantitative traits of weight changes and lipid profiles in a Chinese Han population. A total of 339 schizophrenic patients, including 86 first-episode patients (FEPs), meeting the entry criteria were collected. All patients received atypical antipsychotic drug monotherapy and hospitalization and were followed for 12 weeks. Forty-three SNPs in 23 candidate genes were calculated for quantitative genetic association with AIWG, performed by PLINK...
March 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28315932/body-and-liver-fat-content-and-adipokines-in-schizophrenia-a-magnetic-resonance-imaging-and-spectroscopy-study
#14
Jong-Hoon Kim, Jung-Hyun Kim, Pil-Whan Park, Jürgen Machann, Michael Roden, Sheen-Woo Lee, Jong-Hee Hwang
RATIONALE: Although antipsychotic treatment often causes weight gain and lipid abnormalities, quantitative analyses of tissue-specific body fat content and its distribution along with adipokines have not been reported for antipsychotic-treated patients. OBJECTIVES: The purposes of the present study were to quantitatively assess abdominal and liver fat in patients with schizophrenia on antipsychotic treatment and age- and body mass index (BMI)-matched healthy controls and to evaluate their associations with plasma leptin and adiponectin levels...
March 18, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28306564/psychopharmacological-treatment-of-schizophrenia-during-pregnancy-and-lactation
#15
Alexandra B Whitworth
PURPOSE OF REVIEW: It is necessary, in every-day clinical life when treating pregnant women with mental diseases, to reach quick decisions derived from recent comprehensive information. The knowledge of the use of antipsychotics in pregnancy has increased considerably in the last years. This review tries to summarize important considerations and facilitate clinical decisions. RECENT FINDINGS: This review will cover not only the effects of exposure during pregnancy on outcomes, postnatal adaption syndrome and lactation, but also pharmacokinetic considerations on the use of antipsychotics during pregnancy...
May 2017: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/28300948/superwellness-program-a-cognitive-behavioral-therapy-based-group-intervention-to-reduce-weight-gain-in-patients-treated-with-antipsychotic-drugs
#16
Laura R Magni, Clarissa Ferrari, Giuseppe Rossi, Elena Staffieri, Aldo Uberti, Dario Lamonaca, Ileana Boggian, Silvia Merlin, Giuseppe Primerano, Alessandra Mombrini, Roberto Poli, Francesco M Saviotti, Maria T Caldera, Luciana Zanotti, Roberta Rossi
Objective: To assess the effectiveness of a cognitive-behavioral therapy-based intervention (Superwellness Program) on weight gain compared with a treatment-as-usual (TAU) approach in patients treated with antipsychotics, and to evaluate the relationship between body mass index (BMI) variation and clinical variables. Method: Eighty-five patients treated with antipsychotics were allocated across two groups, experimental (n=59) and control (n=26). The Superwellness Program (experimental group) consisted of 32 twice-weekly 1-hour sessions, conducted by a psychologist and a nutritionist/nurse, concurrently with moderate food intake and moderate physical activity plans...
March 13, 2017: Revista Brasileira de Psiquiatria
https://www.readbyqxmd.com/read/28271424/a-randomized-controlled-multisite-study-of-behavioral-interventions-for-veterans-with-mental-illness-and-antipsychotic-medication-associated-obesity
#17
Zachary D Erickson, Crystal L Kwan, Hollie A Gelberg, Irina Y Arnold, Valery Chamberlin, Jennifer A Rosen, Chandresh Shah, Charles T Nguyen, Gerhard Hellemann, Dixie R Aragaki, Charles F Kunkel, Melissa M Lewis, Neena Sachinvala, Patrick A Sonza, Joseph M Pierre, Donna Ames
BACKGROUND: Weight gain and other metabolic sequelae of antipsychotic medications can lead to medication non-adherence, reduced quality of life, increased costs, and premature mortality. Of the approaches to address this, behavioral interventions are less invasive, cost less, and can result in sustained long-term benefits. OBJECTIVE: We investigated behavioral weight management interventions for veterans with mental illness across four medical centers within the Veterans Affairs (VA) Healthcare System...
April 2017: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/28265714/a-short-history-of-the-5-ht2c-receptor-from-the-choroid-plexus-to-depression-obesity-and-addiction-treatment
#18
REVIEW
Jose M Palacios, Angel Pazos, Daniel Hoyer
This paper is a personal account on the discovery and characterization of the 5-HT2C receptor (first known as the 5-HT1C receptor) over 30 years ago and how it translated into a number of unsuspected features for a G protein-coupled receptor (GPCR) and a diversity of clinical applications. The 5-HT2C receptor is one of the most intriguing members of the GPCR superfamily. Initially referred to as 5-HT1CR, the 5-HT2CR was discovered while studying the pharmacological features and the distribution of [(3)H]mesulergine-labelled sites, primarily in the brain using radioligand binding and slice autoradiography...
March 7, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28264635/lurasidone-compared-to-other-atypical-antipsychotic-monotherapies-for-bipolar-depression-a-systematic-review-and-network-meta-analysis
#19
Michael Ostacher, Daisy Ng-Mak, Pankaj Patel, Dionysios Ntais, Max Schlueter, Antony Loebel
OBJECTIVES: To assess the efficacy and tolerability of lurasidone versus other atypical antipsychotic monotherapy agents in patients with bipolar depression, using a Bayesian network meta-analysis. METHODS: Fourteen randomised clinical trials (6221 patients) of lurasidone, quetiapine (extended release and immediate release), aripiprazole, olanzapine, and ziprasidone for bipolar depression were included. Efficacy assessments included change in the Montgomery-Åsberg Depression Rating Scale (MADRS), rates of response (≥50% improvement in MADRS) and remission (MADRS ≤12 at study endpoint), and change in the Clinical Global Impressions-Bipolar Disorder-Severity (CGI-BP-S) scale...
March 7, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28230072/improved-social-interaction-recognition-and-working-memory-with-cannabidiol-treatment-in-a-prenatal-infection-poly-i-c-rat-model
#20
Ashleigh L Osborne, Nadia Solowij, Ilijana Babic, Xu-Feng Huang, Katrina Weston-Green
Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties, however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model, we examined the effect of chronic CBD treatment on cognition and social interaction...
February 23, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
keyword
keyword
54097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"